VEGF - RMab RBTVEGFBSB 6050-BSB 6056
Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). As its name implies, VEGF activity is restricted mainly to cells of the vascular endothelium, although it has an effect on a limited number of other cell types (e.g., stimulation monocyte macrophage migration). VEGF has been implicated with poor prognosis in breast cancer. The overexpression of VEGF may be an early step in the process of metastasis, a step involved in the “angiogenic” switch. Although VEGF has been correlated with poor survival, its exact mechanism of action in the progression of tumors remains unclear. VEGF is also released in rheumatoid arthritis in response to TNF-alpha, increasing endothelial permeability and swelling and also stimulating angiogenesis (formation of capillaries). Once released, VEGF may elicit several responses. It may cause a cell to survive, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved by the FDA in 2004.
Available options include prediluted (3ml, 7 ml, 15ml), concentrate (0.1 ml, 0.5ml, 1ml) and 5+ control slides.
For Research Use Only.